Seer Stock (NASDAQ:SEER)
Previous Close
$2.39
52W Range
$1.51 - $2.63
50D Avg
$2.38
200D Avg
$1.97
Market Cap
$140.34M
Avg Vol (3M)
$233.01K
Beta
1.46
Div Yield
-
SEER Company Profile
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
SEER Performance
Peer Comparison
| Ticker | Company |
|---|---|
| MLYS | Mineralys Therapeutics, Inc. |
| PHVS | Pharvaris N.V. |
| HCWB | HCW Biologics Inc. |
| MOLN | Molecular Partners AG |
| FHTX | Foghorn Therapeutics Inc. |
| CCCC | C4 Therapeutics, Inc. |
| MNOV | MediciNova, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| QSI | Quantum-Si incorporated |
| NKTX | Nkarta, Inc. |
| NRIX | Nurix Therapeutics, Inc. |
| SANA | Sana Biotechnology, Inc. |
| LYEL | Lyell Immunopharma, Inc. |
| KYMR | Kymera Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| ORIC | ORIC Pharmaceuticals, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| GBIO | Generation Bio Co. |
| ANTX | AN2 Therapeutics, Inc. |
| PEPG | PepGen Inc. |
| STTK | Shattuck Labs, Inc. |